312 related articles for article (PubMed ID: 34639012)
1. MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells.
Cassandri M; Pomella S; Rossetti A; Petragnano F; Milazzo L; Vulcano F; Camero S; Codenotti S; Cicchetti F; Maggio R; Festuccia C; Gravina GL; Fanzani A; Megiorni F; Catanoso M; Marchese C; Tombolini V; Locatelli F; Rota R; Marampon F
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639012
[TBL] [Abstract][Full Text] [Related]
2. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
[TBL] [Abstract][Full Text] [Related]
3. The HDAC3-SMARCA4-miR-27a axis promotes expression of the
Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Ishikawa Y; Zientek K; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Rudek MA; Xu L; Anders NM; Pal R; Harrold AP; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Chatterjee B; Bächinger HP; Barr FG; Liddle J; Garcia BA; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459282
[TBL] [Abstract][Full Text] [Related]
4. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma.
Sun W; Chatterjee B; Shern JF; Patidar R; Song Y; Wang Y; Walker RL; Pawel BR; Linardic CM; Houghton P; Hewitt SM; Edelman DC; Khan J; Meltzer PS; Barr FG
Int J Cancer; 2019 Jun; 144(11):2707-2717. PubMed ID: 30565669
[TBL] [Abstract][Full Text] [Related]
5. Pro-differentiating and radiosensitizing effects of inhibiting HDACs by PXD-101 (Belinostat) in in vitro and in vivo models of human rhabdomyosarcoma cell lines.
Marampon F; Di Nisio V; Pietrantoni I; Petragnano F; Fasciani I; Scicchitano BM; Ciccarelli C; Gravina GL; Festuccia C; Del Fattore A; Tombolini M; De Felice F; Musio D; Cecconi S; Tini P; Maddalo M; Codenotti S; Fanzani A; Polimeni A; Maggio R; Tombolini V
Cancer Lett; 2019 Oct; 461():90-101. PubMed ID: 31325529
[TBL] [Abstract][Full Text] [Related]
6. Romidepsin (FK228) fails in counteracting the transformed phenotype of rhabdomyosarcoma cells but efficiently radiosensitizes, in vitro and in vivo, the alveolar phenotype subtype.
Rossetti A; Petragnano F; Milazzo L; Vulcano F; Macioce G; Codenotti S; Cassandri M; Pomella S; Cicchetti F; Fasciani I; Antinozzi C; Di Luigi L; Festuccia C; De Felice F; Vergine M; Fanzani A; Rota R; Maggio R; Polimeni A; Tombolini V; Gravina GL; Marampon F
Int J Radiat Biol; 2021; 97(7):943-957. PubMed ID: 33979259
[TBL] [Abstract][Full Text] [Related]
7. Hyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells.
De Salvo M; Raimondi L; Vella S; Adesso L; Ciarapica R; Verginelli F; Pannuti A; Citti A; Boldrini R; Milano GM; Cacchione A; Ferrari A; Collini P; Rosolen A; Bisogno G; Alaggio R; Inserra A; Locatelli M; Stifani S; Screpanti I; Miele L; Locatelli F; Rota R
PLoS One; 2014; 9(5):e96238. PubMed ID: 24797362
[TBL] [Abstract][Full Text] [Related]
8. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J
Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416
[TBL] [Abstract][Full Text] [Related]
9. The botanical drug PBI-05204, a supercritical CO
Vaccaro S; Rossetti A; Porrazzo A; Camero S; Cassandri M; Pomella S; Tomaciello M; Macioce G; Pedini F; Barillari G; Marchese C; Rota R; Cenci G; Tombolini M; Newman RA; Yang P; Codenotti S; Fanzani A; Megiorni F; Festuccia C; Minniti G; Gravina GL; Vulcano F; Milazzo L; Marampon F
Front Pharmacol; 2022; 13():1071176. PubMed ID: 36532747
[TBL] [Abstract][Full Text] [Related]
10. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma.
Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG
J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962
[TBL] [Abstract][Full Text] [Related]
11. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma.
Sobral LM; Hicks HM; Parrish JK; McCann TS; Hsieh J; Goodspeed A; Costello JC; Black JC; Jedlicka P
Mol Oncol; 2020 Oct; 14(10):2471-2486. PubMed ID: 32697014
[TBL] [Abstract][Full Text] [Related]
12. Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death.
Ommer J; Selfe JL; Wachtel M; O'Brien EM; Laubscher D; Roemmele M; Kasper S; Delattre O; Surdez D; Petts G; Kelsey A; Shipley J; Schäfer BW
Cancer Res; 2020 Feb; 80(4):832-842. PubMed ID: 31888889
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical detection of PAX-FOXO1 fusion proteins in alveolar rhabdomyosarcoma using breakpoint specific monoclonal antibodies.
Azorsa DO; Bode PK; Wachtel M; Cheuk ATC; Meltzer PS; Vokuhl C; Camenisch U; Khov HL; Bode B; Schäfer BW; Khan J
Mod Pathol; 2021 Apr; 34(4):748-757. PubMed ID: 33299109
[TBL] [Abstract][Full Text] [Related]
14. KDM3B inhibitors disrupt the oncogenic activity of PAX3-FOXO1 in fusion-positive rhabdomyosarcoma.
Kim YY; Gryder BE; Sinniah R; Peach ML; Shern JF; Abdelmaksoud A; Pomella S; Woldemichael GM; Stanton BZ; Milewski D; Barchi JJ; Schneekloth JS; Chari R; Kowalczyk JT; Shenoy SR; Evans JR; Song YK; Wang C; Wen X; Chou HC; Gangalapudi V; Esposito D; Jones J; Procter L; O'Neill M; Jenkins LM; Tarasova NI; Wei JS; McMahon JB; O'Keefe BR; Hawley RG; Khan J
Nat Commun; 2024 Feb; 15(1):1703. PubMed ID: 38402212
[TBL] [Abstract][Full Text] [Related]
15. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
[TBL] [Abstract][Full Text] [Related]
16. PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma.
Hanna JA; Garcia MR; Go JC; Finkelstein D; Kodali K; Pagala V; Wang X; Peng J; Hatley ME
Cell Death Dis; 2016 Jun; 7(6):e2256. PubMed ID: 27277678
[TBL] [Abstract][Full Text] [Related]
17. Investigation of PAX3/7-FKHR fusion genes and IGF2 gene expression in rhabdomyosarcoma tumors.
de Souza RR; Oliveira ID; Caran EM; Alves MT; Abib S; Toledo SR
Growth Horm IGF Res; 2012 Dec; 22(6):245-9. PubMed ID: 23079386
[TBL] [Abstract][Full Text] [Related]
18. Cancer-Specific Energy Metabolism in Rhabdomyosarcoma Cells Is Regulated by MicroRNA.
Sugito N; Taniguchi K; Kuranaga Y; Ohishi M; Soga T; Ito Y; Miyachi M; Kikuchi K; Hosoi H; Akao Y
Nucleic Acid Ther; 2017 Dec; 27(6):365-377. PubMed ID: 28981396
[TBL] [Abstract][Full Text] [Related]
19. BAF complexes drive proliferation and block myogenic differentiation in fusion-positive rhabdomyosarcoma.
Laubscher D; Gryder BE; Sunkel BD; Andresson T; Wachtel M; Das S; Roschitzki B; Wolski W; Wu XS; Chou HC; Song YK; Wang C; Wei JS; Wang M; Wen X; Ngo QA; Marques JG; Vakoc CR; Schäfer BW; Stanton BZ; Khan J
Nat Commun; 2021 Nov; 12(1):6924. PubMed ID: 34836971
[TBL] [Abstract][Full Text] [Related]
20. The RNA helicase DDX5 cooperates with EHMT2 to sustain alveolar rhabdomyosarcoma growth.
Gualtieri A; Bianconi V; Renzini A; Pieroni L; Licursi V; Mozzetta C
Cell Rep; 2022 Aug; 40(9):111267. PubMed ID: 36044855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
